Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -1M |
| Operating Income | -123M | -169M | -165M | -163M | -174M |
| EBITDA | -122M | -157M | -143M | -158M | -170M |
| Net Income | -3M | -157M | -118M | 47M | -111M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$10.72
+1.28% today
1Y Change
+193.71%
Window
Jun 25, 2025 → Jun 18, 2026
Coverage: 248 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Omeros Corporation (OMER) is a Healthcare stock with a market cap of $1.08B and listed on NASDAQ. The stock last traded around $10.71 and up 193.7% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +98.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +98.0%, free cash flow +22.0% with operating margin 0.0% and ROIC -45.3%. Stock Foundry combines OMER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OMER
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OMER Max Drawdown
-49.13%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for OMER and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$111.4M
-335.0% YoY
Free Cash Flow
-$110.0M
-27.0% YoY
Revenue Growth
+0.0%
EPS Growth
+98.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -1M |
| Operating Income | -123M | -169M | -165M | -163M | -174M |
| EBITDA | -122M | -157M | -143M | -158M | -170M |
| Net Income | -3M | -157M | -118M | 47M | -111M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10M | 3M | 7M | 11M | 101M |
| Total Assets | 326M | 277M | 378M | 591M | 419M |
| Total Liabilities | 447M | 460M | 403M | 505M | 395M |
| Shareholder Equity | -121M | -183M | -25M | 86M | 24M |
| Total Debt | 239M | 207M | 362M | 342M | 348M |
| Net Debt | 229M | 204M | 354M | 331M | 247M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
110M
-26.9% YoY
Capital Expenditures
277K
-145.1% YoY
Free Cash Flow
110M
-27.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1.7%
Debt / Equity
-1.97x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.